ClinicalTrials.gg
CompletedNCT04294667PHOENYCS GOUpdated May 4, 2025Results posted

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

A Phase 3 interventional study of DZP and Placebo in Systemic Lupus Erythematosus, sponsored by UCB Biopharma SRL. Completed at 177 sites in 25 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2025-05-04.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
321
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies in Lupus Erythematosus, Systemic by UCB S.A. — 4 open to participants now, 4 under way, 2 of them phase 3. Lupus Erythematosus, Systemic · UCB S.A..

Enrollment
7th of 21
321 · median 54
Started
2020
the only one that year
Phase 3
9 of 21
2 open now
Registered
17th of 21
by date

Among the 21 studies in Lupus Erythematosus, Systemic by UCB S.A., this one is the 7th largest by enrollment, is the only one that started in 2020, is one of 9 in phase 3, and was the 17th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

4 of the 21 studies in Lupus Erythematosus, Systemic by UCB S.A. are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Lupus Erythematosus, Systemic by UCB S.A., or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.

03

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • Systemic lupus erythematosus
  • Dapirolizumab pegol
  • SLE
  • DZP
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Rescreening will be allowed once during the study in case there is new evidence for an inclusion criterion that was not fulfilled at the first screening or in case a study participant no longer meets an exclusion criterion or screening period exceeded the maximum duration due to delays in screening processes
  • Study participant must be ≥16 years of age, unless restricted by local regulation, at the time of signing the form (ICF)
  • Study participants who have moderate to severe disease activity due to either persisting active SLE or due to an acute worsening of SLE in the scope of frequent flaring/relapsing-remitting systemic lupus erythematosus (SLE) despite stable standard of care (SOC) medication defined as:

    a. Diagnosed with SLE at least 24 weeks before the Screening Visit (Visit 1) study entry by a qualified physician b. Classified by 2019 SLE European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria for SLE c. With serological evidence for SLE at Screening as demonstrated by at least 1 of the following: i) Evidence for anti-dsDNA (in central laboratory at Screening) ii) Either complement C3 \< lower limit of normal (LLN) OR complement C4 \<LLN OR elevated erythrocyte-bound complement C4d (where available) as measured by central laboratory iii) Antinuclear antibodies with a titer of at least 1:80 confirmed by central laboratory in combination with evidence of at least 1 of the following SLE typical autoantibodies:

    1. Anti-Smith (anti-Sm) antibodies (central laboratory) 2. Anti-Sjögren's syndrome antibody A (Anti-SSA) (Ro)/Anti-Sjögren's syndrome antibody B (anti-SSB) (La) autoantibodies (central laboratory) 3. Historic evidence for anti-dsDNA antibodies

    d. Moderately to severely active defined as

  • British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004) Grade B in ≥2 organ systems and/or a BILAG 2004 Grade A in ≥1 organ systems at Screening and Baseline Visit AND
  • Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) ≥6 at Screening Visit AND
  • SLEDAI-2K without labs ≥4 at Baseline Visit

    e. Receiving the following SOC medication at stable dose:

    • Antimalarial treatment in combination with and/or or as stand-alone treatment if justified OR Treatment with corticosteroids and/or immunosuppressants if anti-malarial treatment is not possible

Exclusion criteria

Exclusion Criteria:

  • Study participant has any medical or psychiatric condition (including conditions due to neuropsychiatric systemic lupus erythematosus (SLE)) that, in the opinion of the Investigator, could jeopardize or would compromise the study participant's ability to participate in this study. This includes study participants with a life threatening condition
  • Study participant has a history of an anaphylactic reaction to parenteral administration of contrast agents, human or murine proteins, or monoclonal antibodies
  • Study participant has a history of , except the following treated cancers: cervical carcinoma in situ, basal cell carcinoma, or dermatological squamous cell carcinoma
  • Study participant has an increased risk for thromboembolic events due to an ongoing heart disease or due to a medical device, including but not limited to vascular graft, valvular heart disease, atrial fibrillation, or a heart rhythm disorder
  • Study participant has evidence of (HIV) infection, agammaglobulinemias, T-cell deficiencies, or human T-cell lymphotropic virus-1 infection
  • Study participant had a reactivated latent infection (example, cytomegalovirus, herpes simplex virus, or herpes zoster infection) or opportunistic infection (including but not limited to, pneumocystis, cytomegalovirus, or severe herpes zoster infection) within 12 weeks prior to the first study medication infusion (Visit 2), or is currently receiving suppressive therapy for an opportunistic infection
  • Study participants who have received live/ within 6 weeks prior to the first study medication infusion
  • Study participant has active or latent infection
  • Study participant has a mixed connective tissue disease, scleroderma, and/or overlap syndrome of these diseases with SLE
  • Study participant takes any protocol defined prohibited concomitant medication
  • Study participant has previously been randomized within this study or participant has previously been assigned to treatment with dapirolizumab pegol (DZP) in a study evaluating DZP
  • Study participant has participated in another study of an IMP within the previous 12 weeks or 5 half-lives of the medicinal product (IMP) whatever is longer or is currently participating in another study of an IMP
  • Study participant has chronic kidney failure stage 4, manifested by estimated \<30mL/min/1.73m\^2, or serum creatinine >2.5 mg/dL, or participant has proteinuria >3 g/day, or protein: creatinine ratio >340 mg/mmol at the Screening Visit
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
321 participants (actual)

Study arms

  • Experimental
    Dapirolizumab pegol

    Subjects will receive dapriolizumab pegol througout the Treatment Period.

    Drug: DZP

  • Placebo comparator
    Placebo

    Subjects will receive placebo througout the Treatment Period.

    Other: Placebo

Interventions

  • DrugDZP

    Subjects will receive dapirolizumab pegol at prespecified time-points.

    Also known as: CDP7657

  • OtherPlacebo

    Subjects will receive placebo at prespecified time-points.

    Also known as: PBO

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Achievement of BILAG 2004-based Composite Lupus Assessment (BICLA) Response at Week 48

    Study participants were considered to be a BILAG 2004-based Composite Lupus Assessment (BICLA) responder if all of the following were fulfilled: * British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004) improvement without worsening (A scores at Baseline improved to B, C or D; B scores improved to C or D; no new A scores and less than or equal to \[≤\] 1 new B.); Here, score A ("Active"): Severely active disease; score B ("Beware"): Moderately active disease; score C ("Contentment"): Mild stable disease; score D ("Discount"): Inactive now but previously active; and * No worsening in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score compared to Baseline Visit (defined as no increase in SLEDAI-2K total score); and * No worsening in the Physician's Global Assessment of Disease (PGA) compared to Baseline Visit defined as \[≤\] 10 millimeter (mm) increase on a 100 mm visual analog scale (VAS).

    Time frame: Week 48

Secondary outcomes

  1. Percentage of Participants With Achievement of BICLA Response at Week 24

    Study participants were considered to be a BICLA responder if all of the following were fulfilled: * BILAG 2004 improvement without worsening (A scores at Baseline improved to B, C or D; B scores improved to C or D; no new A scores and ≤ 1 new B.); Here, score A ("Active"): Severely active disease; score B ("Beware"): Moderately active disease; score C ("Contentment"): Mild stable disease; score D ("Discount"): Inactive now but previously active; and * No worsening in the SLEDAI-2K total score compared to Baseline Visit (defined as no increase in SLEDAI-2K total score); and * No worsening in the PGA compared to Baseline Visit defined as ≤ 10 mm increase on a 100 mm VAS.

    Time frame: Week 24

  2. Percentage of Participants With Achievement of BICLA Response at Week 12

    Study participants were considered to be a BICLA responder if all of the following were fulfilled: * BILAG 2004 improvement without worsening (A scores at Baseline improved to B, C or D; B scores improved to C or D; no new A scores and ≤ 1 new B.); Here, score A ("Active"): Severely active disease; score B ("Beware"): Moderately active disease; score C ("Contentment"): Mild stable disease; score D ("Discount"): Inactive now but previously active and * No worsening in the SLEDAI-2K total score compared to Baseline Visit (defined as no increase in SLEDAI-2K total score); and * No worsening in the PGA compared to Baseline Visit defined as ≤ 10 mm increase on a 100 mm VAS.

    Time frame: Week 12

  3. Percentage of Participants With Achievement of Prevention of Severe British Isles Lupus Assessment Group (BILAG) Flares (Severe BILAG Flare-free) Through Week 48

    A severe BILAG flare was defined as a british isles lupus assessment group disease activity index 2004 (BILAG 2004) Grade A in any system due to individual items that were new or worse qualifying for the Grade A. Determination of items that were new or worse and were qualifying for the Grade A were according to the supplementary information for the numerical scoring of the BILAG-2004 index. Here, Grade A ("Active"): Severely active disease (sufficient to require systemic immunosuppressant or anticoagulant therapy.

    Time frame: During Treatment Period up to Week 48

  4. Percentage of Participants With Achievement of Lupus Low Disease Activity State (LLDAS) in ≥50% of Post-Baseline Visits Through Week 48

    The LLDAS includes domains that capture the absence of organ-threatening disease activity and harmful treatment burden. The LLDAS is defined as: * SLEDAI-2K score was ≤4 with no activity in major organ systems. * No new and/or worsening disease activity defined as no SLEDAI-2K component documented as present that was not documented present at the previous visit. * PGA ≤ 33 mm. * Prednisone equivalent systemic dose for systemic lupus erythematosus (SLE) indication ≤ 7.5 mg per day. * Stable standard maintenance doses of immunosuppressive drugs as allowed by protocol, defined as no increase in dose in the past 12 weeks and no dose higher than allowed as per protocol.

    Time frame: During Treatment Period up to Week 48

  5. Change From Baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) at Week 48

    The SLEDAI-2K is a global index which includes 24 clinical and laboratory variables such as antibodies, renal, and hematological components measured 30 days before, and at the timepoint of assessment. The variables were weighted by the type of manifestation, but not by severity or dynamic of the individual item. The SLEDAI-2K includes scoring for antibodies (anti-dsDNA positive or negative) and low complement, as well as some renal and hematologic parameters. The total score falls between 0 and 105, with higher scores representing increased disease activity. Mixed effects models for repeated measurements (MMRM).

    Time frame: From Baseline (Day 1) to Week 48

  6. Percentage of Participants With Achievement of BILAG Improvement Without Worsening at Week 48

    The BILAG improvement without worsening defined as A scores at Baseline improved to B, C or D; B scores improved to C or D; no new A scores and ≤1 new B Score. Here, score A ("Active"): Severely active disease (sufficient to require systemic immunosuppressant or anticoagulant therapy; score B ("Beware"): Moderately active disease (requires low dose or local immunosuppressant therapy or symptomatic therapy; score C ("Contentment"): Mild stable disease (no indication for changes in treatment); score D ("Discount"): Inactive now but previously active.

    Time frame: Week 48

  7. Change From Baseline in Physician's Global Assessment (PGA) at Week 48

    The PGA is a measure of systemic lupus erythematosus (SLE) signs and symptoms by the physician using a visual analog scale of 0 to 100mm, Where 0 indicate "very good", asymptomatic, and no limitation of normal activity and 100 indicate "severe disease".

    Time frame: From Baseline (Day 1) to Week 48

  8. Percentage of Participants With Achievement of Systemic Lupus Erythematosus Responder Index Response - 4 (SRI-4) Response at Week 48

    The SRI-4 define responders as meeting all of the following criteria: * Reduction in SLEDAI-2K score of ≥ 4. * No shift from BILAG 2004 Grade B, C, D, or E to A post-Baseline. Here, Grade A ("Active"): Severely active disease; Grade B ("Beware"): Moderately active disease; Grade C ("Contentment"): Mild stable disease; Grade D ("Discount"): Inactive now but previously active; Grade E ("Excluded"): Never affected. * No more than 1 shift from BILAG 2004 Grade C, D, or E to B post-Baseline. * No worsening in the PGA compared to study entry defined as ≤ 10 mm increase on a 100 mm visual analog scale, equivalent to less than a 10 mm increase in the PGA compared to study entry score.

    Time frame: Week 48

  9. Percentage of Participants With Achievement of Prevention of Moderate/Severe BILAG Flares (Moderate/Severe BILAG Flare-free) Through Week 48

    Achievement of prevention of moderate/severe BILAG flares through Week 48 was defined as the percentage of participants with no moderate or severe flare through Week 48. A severe BILAG flare was defined as a BILAG 2004 Grade A in any system due to individual items that were new or worse qualifying for the Grade A. Determination of items that were new or worse and were qualifying for the Grade A, according to the supplementary information for the numerical scoring of the BILAG-2004 index. A moderate BILAG flare was defined as 2 or more BILAG 2004 Grade B due to individual items that were new or worse and were qualifying for the Grade B in any system. Determination of items that were new or worse qualifying for the Grade B, according to the supplementary information for the numerical scoring of the BILAG- 2004 index. Here, Grade A ("Active"): Severely active disease; Grade B ("Beware"): Moderately active disease.

    Time frame: During Treatment Period up to Week 48

  10. Time to Severe BILAG Flare Through Week 48

    Time to severe BILAG flare (the event) through Week 48 was defined as the time from randomization until the start of the event. A severe BILAG flare was defined as a BILAG 2004 Grade A in any system due to individual items that were new or worse qualifying for the Grade A. Determination of items that were new or worse and were qualifying for the Grade A, according to the supplementary information for the numerical scoring of the BILAG-2004 index. Here, Grade A ("Active"): Severely active disease.

    Time frame: During Treatment Period up to Week 48

  11. Time to Moderate/Severe BILAG Flare Through Week 48

    Time to moderate/severe BILAG flare (the event) through Week 48 was defined as the time from randomization until the start of the event. Moderate BILAG flare was defined as 2 or more BILAG 2004 Grade B due to individual items that were new or worse and were qualifying for the Grade B in any system. Determination of items that were new or worse qualifying for the Grade B, according to the supplementary information for the numerical scoring of the BILAG-2004 index. Severe BILAG flare was defined as a BILAG 2004 Grade A in any system due to individual items that were new or worse qualifying for the Grade A. Determination of items that were new or worse and are qualifying for the Grade A, according to the supplementary information for the numerical scoring of the BILAG-2004 index. Here, Grade A ("Active"): Severely active disease; Grade B ("Beware"): Moderately active disease.

    Time frame: During Treatment Period up to Week 48

  12. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. Treatment-emergent AEs were those with onset date on or after the first administration of study drug, and up to 60 days after last dose.

    Time frame: From Baseline (Day 1) until Safety Follow-Up (up to Week 54)

  13. Percentage of Participants With Serious Treatment-emergent Adverse Events During the Study

    A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: Results in death; Is life-threatening, Requires in patient hospitalization or prolongation of existing hospitalization; Results in persistent disability/incapacity; Is a congenital anomaly/birth defect; and Other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above. Treatment-emergent AEs were those with onset date on or after the first administration of study drug, and up to 60 days after last dose.

    Time frame: From Baseline (Day 1) until Safety Follow-Up (up to Week 54)

  14. Percentage of Participants With Treatment-emergent Adverse Events of Special Interest During the Study

    An adverse event of special interest (AESIs) is any AE that a regulatory authority has mandated be reported on an expedited basis, regardless of the seriousness, expectedness, or relatedness of the AE to the administration of a product/compound.

    Time frame: From Baseline (Day 1) until Safety Follow-Up (up to Week 54)

  15. Percentage of Participants With Treatment-emergent Adverse Events of Special Monitoring During the Study

    An AE of special monitoring is a product-specific AEs, adverse reactions, or safety topics considered as requiring special monitoring by UCB.

    Time frame: From Baseline (Day 1) until Safety Follow-Up (up to Week 54)

07

Results

Posted Apr 24, 2025

Participant flow

The study started to enroll participants in August 2020 and concluded in June 2024.

Participant flow — Overall Study
MilestonePBO+SOCDZP+SOC
Started108213
Completed91192
Not completed1721
Withdrew: Lack of efficacy44
Withdrew: Consent withdrawal by study participant97
Withdrew: Patient has a renal flare10
Withdrew: Sle worsening01
Withdrew: Subject decision due to personal reason01
Withdrew: Pi closed site - subject early withdrawal01
Withdrew: Subject withdrew due to personal reason01
Withdrew: Subject moved to another state01
Withdrew: Adverse event, serious fatal01
Withdrew: Adverse event, non-fatal34

Outcome measures

PrimaryPercentage of Participants With Achievement of BILAG 2004-based Composite Lupus Assessment (BICLA) Response at Week 48

Study participants were considered to be a BILAG 2004-based Composite Lupus Assessment (BICLA) responder if all of the following were fulfilled: * British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004) improvement without worsening (A scores at Baseline improved to B, C or D; B scores improved to C or D; no new A scores and less than or equal to \[≤\] 1 new B.); Here, score A ("Active"): Severely active disease; score B ("Beware"): Moderately active disease; score C ("Contentment"): Mild stable disease; score D ("Discount"): Inactive now but previously active; and * No worsening in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score compared to Baseline Visit (defined as no increase in SLEDAI-2K total score); and * No worsening in the Physician's Global Assessment of Disease (PGA) compared to Baseline Visit defined as \[≤\] 10 millimeter (mm) increase on a 100 mm visual analog scale (VAS).

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Achievement of BILAG 2004-based Composite Lupus Assessment (BICLA) Response at Week 48
percentage of participantsPBO+SOCDZP+SOC
Percentage of Participants With Achievement of BILAG 2004-based Composite Lupus Assessment (BICLA) Response at Week 4834.649.5
Statistical analysis
  • PBO+SOC vs DZP+SOC · Cochran-Mantel-Haenszel · p = 0.0110 · Difference in proportions (%): 14.6 · 95% CI 3.3 to 25.8
SecondaryPercentage of Participants With Achievement of BICLA Response at Week 24

Study participants were considered to be a BICLA responder if all of the following were fulfilled: * BILAG 2004 improvement without worsening (A scores at Baseline improved to B, C or D; B scores improved to C or D; no new A scores and ≤ 1 new B.); Here, score A ("Active"): Severely active disease; score B ("Beware"): Moderately active disease; score C ("Contentment"): Mild stable disease; score D ("Discount"): Inactive now but previously active; and * No worsening in the SLEDAI-2K total score compared to Baseline Visit (defined as no increase in SLEDAI-2K total score); and * No worsening in the PGA compared to Baseline Visit defined as ≤ 10 mm increase on a 100 mm VAS.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Achievement of BICLA Response at Week 24
percentage of participantsPBO+SOCDZP+SOC
Percentage of Participants With Achievement of BICLA Response at Week 2438.346.6
Statistical analysis
  • PBO+SOC vs DZP+SOC · Cochran-Mantel-Haenszel · p = 0.1776 · Difference in proportions (%): 7.9 · 95% CI -3.6 to 19.4
SecondaryPercentage of Participants With Achievement of BICLA Response at Week 12

Study participants were considered to be a BICLA responder if all of the following were fulfilled: * BILAG 2004 improvement without worsening (A scores at Baseline improved to B, C or D; B scores improved to C or D; no new A scores and ≤ 1 new B.); Here, score A ("Active"): Severely active disease; score B ("Beware"): Moderately active disease; score C ("Contentment"): Mild stable disease; score D ("Discount"): Inactive now but previously active and * No worsening in the SLEDAI-2K total score compared to Baseline Visit (defined as no increase in SLEDAI-2K total score); and * No worsening in the PGA compared to Baseline Visit defined as ≤ 10 mm increase on a 100 mm VAS.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Achievement of BICLA Response at Week 12
percentage of participantsPBO+SOCDZP+SOC
Percentage of Participants With Achievement of BICLA Response at Week 1229.039.9
Statistical analysis
  • PBO+SOC vs DZP+SOC · Cochran-Mantel-Haenszel · p = 0.0518 · Difference in proportions (%): 10.8 · 95% CI -0.1 to 21.7
SecondaryPercentage of Participants With Achievement of Prevention of Severe British Isles Lupus Assessment Group (BILAG) Flares (Severe BILAG Flare-free) Through Week 48

A severe BILAG flare was defined as a british isles lupus assessment group disease activity index 2004 (BILAG 2004) Grade A in any system due to individual items that were new or worse qualifying for the Grade A. Determination of items that were new or worse and were qualifying for the Grade A were according to the supplementary information for the numerical scoring of the BILAG-2004 index. Here, Grade A ("Active"): Severely active disease (sufficient to require systemic immunosuppressant or anticoagulant therapy.

Time frame:
During Treatment Period up to Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Achievement of Prevention of Severe British Isles Lupus Assessment Group (BILAG) Flares (Severe BILAG Flare-free) Through Week 48
percentage of participantsPBO+SOCDZP+SOC
Percentage of Participants With Achievement of Prevention of Severe British Isles Lupus Assessment Group (BILAG) Flares (Severe BILAG Flare-free) Through Week 4876.688.4
Statistical analysis
  • PBO+SOC vs DZP+SOC · Cochran-Mantel-Haenszel · p = 0.0257 · Difference in proportions (%): 11.5 · 95% CI 1.4 to 21.6
SecondaryPercentage of Participants With Achievement of Lupus Low Disease Activity State (LLDAS) in ≥50% of Post-Baseline Visits Through Week 48

The LLDAS includes domains that capture the absence of organ-threatening disease activity and harmful treatment burden. The LLDAS is defined as: * SLEDAI-2K score was ≤4 with no activity in major organ systems. * No new and/or worsening disease activity defined as no SLEDAI-2K component documented as present that was not documented present at the previous visit. * PGA ≤ 33 mm. * Prednisone equivalent systemic dose for systemic lupus erythematosus (SLE) indication ≤ 7.5 mg per day. * Stable standard maintenance doses of immunosuppressive drugs as allowed by protocol, defined as no increase in dose in the past 12 weeks and no dose higher than allowed as per protocol.

Time frame:
During Treatment Period up to Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Achievement of Lupus Low Disease Activity State (LLDAS) in ≥50% of Post-Baseline Visits Through Week 48
percentage of participantsPBO+SOCDZP+SOC
Percentage of Participants With Achievement of Lupus Low Disease Activity State (LLDAS) in ≥50% of Post-Baseline Visits Through Week 4815.923.6
Statistical analysis
  • PBO+SOC vs DZP+SOC · Cochran-Mantel-Haenszel · p = 0.1042 · Difference in proportions (%): 7.2 · 95% CI -1.5 to 16.0
SecondaryChange From Baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) at Week 48

The SLEDAI-2K is a global index which includes 24 clinical and laboratory variables such as antibodies, renal, and hematological components measured 30 days before, and at the timepoint of assessment. The variables were weighted by the type of manifestation, but not by severity or dynamic of the individual item. The SLEDAI-2K includes scoring for antibodies (anti-dsDNA positive or negative) and low complement, as well as some renal and hematologic parameters. The total score falls between 0 and 105, with higher scores representing increased disease activity. Mixed effects models for repeated measurements (MMRM).

Time frame:
From Baseline (Day 1) to Week 48
Reported as:
Least squares mean · score on a scale
Change From Baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) at Week 48
score on a scalePBO+SOCDZP+SOC
Change From Baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) at Week 48-4.2 ± 0.39-6.1 ± 0.26
Statistical analysis
  • PBO+SOC vs DZP+SOC · MMRM · p = 0.0001 · Difference of change(dzp+soc vs pbo+soc): -1.8 · 95% CI -2.7 to -0.9The Least Squares (LS) Mean, the difference (DZP+SOC versus PBO+SOC), and the 95% CIs was computed from the MMRM.
SecondaryPercentage of Participants With Achievement of BILAG Improvement Without Worsening at Week 48

The BILAG improvement without worsening defined as A scores at Baseline improved to B, C or D; B scores improved to C or D; no new A scores and ≤1 new B Score. Here, score A ("Active"): Severely active disease (sufficient to require systemic immunosuppressant or anticoagulant therapy; score B ("Beware"): Moderately active disease (requires low dose or local immunosuppressant therapy or symptomatic therapy; score C ("Contentment"): Mild stable disease (no indication for changes in treatment); score D ("Discount"): Inactive now but previously active.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Achievement of BILAG Improvement Without Worsening at Week 48
percentage of participantsPBO+SOCDZP+SOC
Percentage of Participants With Achievement of BILAG Improvement Without Worsening at Week 4834.649.5
SecondaryChange From Baseline in Physician's Global Assessment (PGA) at Week 48

The PGA is a measure of systemic lupus erythematosus (SLE) signs and symptoms by the physician using a visual analog scale of 0 to 100mm, Where 0 indicate "very good", asymptomatic, and no limitation of normal activity and 100 indicate "severe disease".

Time frame:
From Baseline (Day 1) to Week 48
Reported as:
Least squares mean · score on a scale
Change From Baseline in Physician's Global Assessment (PGA) at Week 48
score on a scalePBO+SOCDZP+SOC
Change From Baseline in Physician's Global Assessment (PGA) at Week 48-33.4 ± 1.99-39.6 ± 1.36
SecondaryPercentage of Participants With Achievement of Systemic Lupus Erythematosus Responder Index Response - 4 (SRI-4) Response at Week 48

The SRI-4 define responders as meeting all of the following criteria: * Reduction in SLEDAI-2K score of ≥ 4. * No shift from BILAG 2004 Grade B, C, D, or E to A post-Baseline. Here, Grade A ("Active"): Severely active disease; Grade B ("Beware"): Moderately active disease; Grade C ("Contentment"): Mild stable disease; Grade D ("Discount"): Inactive now but previously active; Grade E ("Excluded"): Never affected. * No more than 1 shift from BILAG 2004 Grade C, D, or E to B post-Baseline. * No worsening in the PGA compared to study entry defined as ≤ 10 mm increase on a 100 mm visual analog scale, equivalent to less than a 10 mm increase in the PGA compared to study entry score.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Achievement of Systemic Lupus Erythematosus Responder Index Response - 4 (SRI-4) Response at Week 48
percentage of participantsPBO+SOCDZP+SOC
Percentage of Participants With Achievement of Systemic Lupus Erythematosus Responder Index Response - 4 (SRI-4) Response at Week 4841.160.1
SecondaryPercentage of Participants With Achievement of Prevention of Moderate/Severe BILAG Flares (Moderate/Severe BILAG Flare-free) Through Week 48

Achievement of prevention of moderate/severe BILAG flares through Week 48 was defined as the percentage of participants with no moderate or severe flare through Week 48. A severe BILAG flare was defined as a BILAG 2004 Grade A in any system due to individual items that were new or worse qualifying for the Grade A. Determination of items that were new or worse and were qualifying for the Grade A, according to the supplementary information for the numerical scoring of the BILAG-2004 index. A moderate BILAG flare was defined as 2 or more BILAG 2004 Grade B due to individual items that were new or worse and were qualifying for the Grade B in any system. Determination of items that were new or worse qualifying for the Grade B, according to the supplementary information for the numerical scoring of the BILAG- 2004 index. Here, Grade A ("Active"): Severely active disease; Grade B ("Beware"): Moderately active disease.

Time frame:
During Treatment Period up to Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Achievement of Prevention of Moderate/Severe BILAG Flares (Moderate/Severe BILAG Flare-free) Through Week 48
percentage of participantsPBO+SOCDZP+SOC
Percentage of Participants With Achievement of Prevention of Moderate/Severe BILAG Flares (Moderate/Severe BILAG Flare-free) Through Week 4863.078.6
SecondaryTime to Severe BILAG Flare Through Week 48

Time to severe BILAG flare (the event) through Week 48 was defined as the time from randomization until the start of the event. A severe BILAG flare was defined as a BILAG 2004 Grade A in any system due to individual items that were new or worse qualifying for the Grade A. Determination of items that were new or worse and were qualifying for the Grade A, according to the supplementary information for the numerical scoring of the BILAG-2004 index. Here, Grade A ("Active"): Severely active disease.

Time frame:
During Treatment Period up to Week 48
Reported as:
Median · weeks
Time to Severe BILAG Flare Through Week 48
weeksPBO+SOCDZP+SOC
Time to Severe BILAG Flare Through Week 48NA (NA to NA)NA (NA to NA)
Statistical analysis
  • PBO+SOC vs DZP+SOC · Log Rank · p = 0.0111
SecondaryTime to Moderate/Severe BILAG Flare Through Week 48

Time to moderate/severe BILAG flare (the event) through Week 48 was defined as the time from randomization until the start of the event. Moderate BILAG flare was defined as 2 or more BILAG 2004 Grade B due to individual items that were new or worse and were qualifying for the Grade B in any system. Determination of items that were new or worse qualifying for the Grade B, according to the supplementary information for the numerical scoring of the BILAG-2004 index. Severe BILAG flare was defined as a BILAG 2004 Grade A in any system due to individual items that were new or worse qualifying for the Grade A. Determination of items that were new or worse and are qualifying for the Grade A, according to the supplementary information for the numerical scoring of the BILAG-2004 index. Here, Grade A ("Active"): Severely active disease; Grade B ("Beware"): Moderately active disease.

Time frame:
During Treatment Period up to Week 48
Reported as:
Median · weeks
Time to Moderate/Severe BILAG Flare Through Week 48
weeksPBO+SOCDZP+SOC
Time to Moderate/Severe BILAG Flare Through Week 48NA (36.1 to NA)NA (NA to NA)
Statistical analysis
  • PBO+SOC vs DZP+SOC · Log Rank · p = 0.0228
SecondaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study

An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. Treatment-emergent AEs were those with onset date on or after the first administration of study drug, and up to 60 days after last dose.

Time frame:
From Baseline (Day 1) until Safety Follow-Up (up to Week 54)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study
percentage of participantsPBO+SOCDZP+SOC
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study75.082.6
SecondaryPercentage of Participants With Serious Treatment-emergent Adverse Events During the Study

A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: Results in death; Is life-threatening, Requires in patient hospitalization or prolongation of existing hospitalization; Results in persistent disability/incapacity; Is a congenital anomaly/birth defect; and Other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above. Treatment-emergent AEs were those with onset date on or after the first administration of study drug, and up to 60 days after last dose.

Time frame:
From Baseline (Day 1) until Safety Follow-Up (up to Week 54)
Reported as:
Number · percentage of participants
Percentage of Participants With Serious Treatment-emergent Adverse Events During the Study
percentage of participantsPBO+SOCDZP+SOC
Percentage of Participants With Serious Treatment-emergent Adverse Events During the Study14.89.9
SecondaryPercentage of Participants With Treatment-emergent Adverse Events of Special Interest During the Study

An adverse event of special interest (AESIs) is any AE that a regulatory authority has mandated be reported on an expedited basis, regardless of the seriousness, expectedness, or relatedness of the AE to the administration of a product/compound.

Time frame:
From Baseline (Day 1) until Safety Follow-Up (up to Week 54)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events of Special Interest During the Study
percentage of participantsPBO+SOCDZP+SOC
Percentage of Participants With Treatment-emergent Adverse Events of Special Interest During the Study0.90
SecondaryPercentage of Participants With Treatment-emergent Adverse Events of Special Monitoring During the Study

An AE of special monitoring is a product-specific AEs, adverse reactions, or safety topics considered as requiring special monitoring by UCB.

Time frame:
From Baseline (Day 1) until Safety Follow-Up (up to Week 54)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events of Special Monitoring During the Study
percentage of participantsPBO+SOCDZP+SOC
Percentage of Participants With Treatment-emergent Adverse Events of Special Monitoring During the Study24.136.6

Adverse events

Collected over From Baseline (Day 1) until Safety Follow-Up (up to Week 54). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PBO+SOC0/108 (0%)16/108 (14.8%)47/108 (43.5%)
DZP+SOC1/213 (0.5%)21/213 (9.9%)109/213 (51.2%)
Most frequent serious events
Showing 10 of 38
Most frequent serious events
EventPBO+SOCDZP+SOC
Systemic lupus erythematosusMusculoskeletal and connective tissue disorders1/1083/213
Ophthalmic herpes zosterInfections and infestations0/1082/213
Infusion related reactionInjury, poisoning and procedural complications0/1082/213
Lupus enteritisGastrointestinal disorders1/1080/213
Chest painGeneral disorders1/1080/213
AppendicitisInfections and infestations1/1080/213
DiverticulitisInfections and infestations1/1080/213
Diverticulitis intestinal perforatedInfections and infestations1/1080/213
Bacterial colitisInfections and infestations1/1080/213
Herpes zosterInfections and infestations1/1080/213
Most frequent other events
Most frequent other events
EventPBO+SOCDZP+SOC
COVID-19Infections and infestations17/10844/213
Urinary tract infectionInfections and infestations9/10828/213
NasopharyngitisInfections and infestations13/10818/213
Upper respiratory tract infectionInfections and infestations8/10820/213
DiarrhoeaGastrointestinal disorders10/10815/213
HeadacheNervous system disorders7/10815/213
NauseaGastrointestinal disorders6/1089/213
Herpes zosterInfections and infestations6/1084/213
Oral herpesInfections and infestations6/1084/213
BronchitisInfections and infestations5/10811/213

Baseline characteristics

Baseline Characteristics refer to the Safety Set (SS) which consisted of all study participants who were randomized and had received at least 1 dose (any amount) of study medication.

Age, Continuous
Age, Continuous(Years)PBO+SOCDZP+SOCTotal
Mean41.5 ± 12.343.8 ± 12.443.0 ± 12.4
Age, Customized
Age, Customized(Participants)PBO+SOCDZP+SOCTotal
12 to <18 Years011
18 to <65 Years106201307
65 to <85 Years21113
Sex: Female, Male
Sex: Female, Male(Participants)PBO+SOCDZP+SOCTotal
Female101198299
Male71522
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PBO+SOCDZP+SOCTotal
American Indian/Alaska native92029
Asian91827
Black or African American101424
Native Hawaiian or other Pacific Islander011
White63130193
Other/Mixed173047
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PBO+SOCDZP+SOCTotal
Hispanic or Latino4078118
Not Hispanic or Latino68135203
08

Study locations

177 sites
  • Sl0043 50140
    Birmingham, Alabama 35205, United States
  • Sl0043 50052
    Phoenix, Arizona 85032, United States
  • Sl0043 50328
    Tucson, Arizona 85704, United States
  • Sl0043 50383
    Beverly Hills, California 90211, United States
  • Sl0043 50257
    La Jolla, California 92037, United States
  • Sl0043 50275
    La Palma, California 90623-1730, United States
  • Sl0043 50378
    Loma Linda, California 92354, United States
  • Sl0043 50258
    Los Angeles, California 90022, United States
  • Sl0043 50340
    Orange, California 92868, United States
  • Sl0043 50331
    Poway, California 92064, United States
  • Sl0043 50377
    San Diego, California 92108, United States
  • Sl0043 50316
    San Leandro, California 94578, United States
  • Sl0043 50339
    Denver, Colorado 80230, United States
  • Sl0043 50367
    New Haven, Connecticut 06519, United States
  • Sl0043 50341
    Washington, District of Columbia 20060, United States
  • Sl0043 50239
    Brandon, Florida 33511, United States
  • Sl0043 50362
    Gainesville, Florida 32610, United States
  • Sl0043 50122
    Miami, Florida 33136, United States
  • Sl0043 50059
    Ormond Beach, Florida 32174, United States
  • Sl0043 50324
    Plantation, Florida 33324, United States
  • Sl0043 50329
    Tampa, Florida 33606, United States
  • Sl0043 50283
    Tampa, Florida 33613, United States
  • Sl0043 50368
    Atlanta, Georgia 30303, United States
  • Sl0043 50382
    Atlanta, Georgia 30309, United States
  • Sl0043 50240
    Idaho Falls, Idaho 83404, United States
  • Sl0043 50310
    Chicago, Illinois 60612, United States
  • Sl0043 50360
    Skokie, Illinois 60076, United States
  • Sl0043 50474
    Hopkinsville, Kentucky 42240-1746, United States
  • Sl0043 50285
    Lake Charles, Louisiana 70605, United States
  • Sl0043 50288
    Cumberland, Maryland 21502, United States
  • Sl0043 50015
    Hagerstown, Maryland 21740, United States
  • Sl0043 50219
    Detroit, Michigan 48201, United States
  • Sl0043 50333
    Grand Blanc, Michigan 48439, United States
  • Sl0043 50273
    Las Vegas, Nevada 89128, United States
  • Sl0043 50010
    Brooklyn, New York 11201, United States
  • Sl0043 50366
    Canton, New York 13617, United States
  • Sl0043 50266
    Great Neck, New York 11021, United States
  • Sl0043 50264
    Manhasset, New York 11030, United States
  • Sl0043 50077
    New York, New York 10021, United States
  • Sl0043 50334
    New York, New York 10032, United States
  • Sl0043 50241
    Syracuse, New York 13210, United States
  • Sl0043 50238
    Charlotte, North Carolina 28211, United States
  • Sl0043 50179
    Winston-Salem, North Carolina 27157-1010, United States
  • Sl0043 50330
    Cincinnati, Ohio 45242, United States
  • Sl0043 50262
    Oklahoma City, Oklahoma 73104, United States
  • Sl0043 50020
    Duncansville, Pennsylvania 16635, United States
  • Sl0043 50147
    Hershey, Pennsylvania 17033, United States
  • Sl0043 50364
    Philadelphia, Pennsylvania 19107, United States
  • Sl0043 50365
    Pittsburgh, Pennsylvania 15232, United States
  • Sl0043 50001
    Jackson, Tennessee 38305, United States
  • Sl0043 50263
    Amarillo, Texas 79124, United States
  • Sl0043 50338
    Bellaire, Texas 77401, United States
  • Sl0043 50418
    Colleyville, Texas 76034, United States
  • Sl0043 50057
    Dallas, Texas 75231, United States
  • Sl0043 50304
    Dallas, Texas 75390, United States
  • Sl0043 50036
    Mesquite, Texas 75150, United States
  • Sl0043 50267
    Seattle, Washington 98195, United States
  • Sl0043 50061
    Spokane, Washington 99204, United States
  • Sl0043 50050
    Beckley, West Virginia 25801, United States
  • Sl0043 50321
    Morgantown, West Virginia 26505, United States
  • Sl0043 60002
    Capital Federal, Argentina
  • Sl0043 60001
    Ciudad Autonoma de Buenos Aire, Argentina
  • Sl0043 60029
    Mendoza, Argentina
  • Sl0043 60003
    Quilmes, Argentina
  • Sl0043 60022
    Quilmes, Argentina
  • Sl0043 60011
    San Juan, Argentina
  • Sl0043 60014
    Tucuman, Argentina
  • Sl0043 30020
    Parkville, Australia
  • Sl0043 30025
    St Albans, Australia
  • Sl0043 40388
    Graz, Austria
  • Sl0043 40387
    Wien, Austria
  • Sl0043 40123
    Bruxelles, Belgium
  • Sl0043 40060
    Liege, Belgium
  • Sl0043 40006
    Plovdiv, Bulgaria
  • Sl0043 40189
    Plovdiv, Bulgaria
  • Sl0043 40522
    Plovdiv, Bulgaria
  • Sl0043 40380
    Sofia, Bulgaria
  • Sl0043 50374
    Calgary, Canada
  • Sl0043 50337
    Edmonton, Canada
  • Sl0043 50259
    Rimouski, Canada
  • Sl0043 50045
    Toronto, Canada
  • Sl0043 50044
    Trois-rivieres, Canada
  • Sl0043 60021
    Providencia, Santiago, Chile
  • Sl0043 60015
    Santiago de Chile, Chile
  • Sl0043 60018
    Santiago, Chile
  • Sl0043 60030
    Santiago, Chile
  • Sl0043 60013
    Barranquilla, Colombia
  • Sl0043 60019
    Barranquilla, Colombia
  • Sl0043 60006
    Bogota, Colombia
  • Sl0043 60027
    Bogota, Colombia
  • Sl0043 60016
    Bucaramanga, Colombia
  • Sl0043 60007
    Chia, Colombia
  • Sl0043 60028
    Medellín, Colombia
  • Sl0043 60031
    Monteria, Colombia
  • Sl0043 40066
    Praha 2, Czechia
  • Sl0043 40489
    Odense, Denmark
  • Sl0043 40506
    Montpellier Cedex 5, France
  • Sl0043 40505
    Paris Cedex 12, France
  • Sl0043 40386
    Cologne, Germany
  • Sl0043 40322
    Dessau, Germany

Showing the first 100 of 177 sites across 25 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed.All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · www.vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in May 2024, 45 months.

Results were first posted in Apr 2025, 11 months after primary completion.

Of 53 phase 3 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 84. This study's 45 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2020
First posted
Mar 4, 2020
StartActual
Aug 12, 2020
Primary completionActual
May 22, 2024
CompletionActual
Jun 4, 2024
Results first posted
Apr 24, 2025
Last update
May 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04294667
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Mar 4, 2020
Start date
Aug 12, 2020
Primary completion
May 22, 2024
Completion
Jun 4, 2024
Results posted
Apr 24, 2025
Last update
May 4, 2025

Study contacts

UCB Cares
study director · 001 844 599 2273 (UCB)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapirolizumab pegol

Start the discussion